The standard of care for obese men starting Androgen deprivation therapy (ADT) is physician
based dietary and exercise counseling. Interventions to lessen the harmful effects of ADT are
needed yet have been limited. Exercise is one strategy that has been attempted however there
is conflicting data as to whether or not exercise effectively improves body mass, results in
sustained weight loss, improvements in metabolic risk profiles including glucose tolerance
and lipid profiles in men starting ADT, or has any effect of progression of cancer. Dietary
interventions have been attempted without clear improvement in weight, metabolic factors,
quality of life or cancer progression. Bariatric arterial embolization (BAE), given it
results in weight loss in obese men and women without cancer, may be able to stave off the
harmful side effects of ADT by inducing weight loss. Therefore, the investigators hypothesize
that Bariatric Arterial embolization (BAE), done prior to initiation of ADT, will mitigate
the weight gain and metabolic side effects associated with ADT, by inducing weight loss of at
least 5% in obese men with biochemical recurrent prostate cancer starting ADT.
The primary objective is to determine if BAE, done prior to ADT initiation in obese men (with
obesity related comorbid condition) with biochemically recurrent prostate cancer, can induce
5% or greater weight loss at 6 months.
Adenocarcinoma of the Prostate,
Adenocarcinoma of Prostate,
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.